Rodríguez-Choreño JD, Morín-Zaragoza R, Ponce-López ML, Alcaraz-Ortiz R, Morales-Suárez MO

Language: Spanish
References: 21
Page: 77-85
PDF size: 180.48 Kb.

ABSTRACT

Objective. To evaluate the efficacy and safety of sequential long-term treatment for obesity with slow release catecholaminergic anorexigenics. Material and methods. A randomized double-blind study with placebo control of 14 months, six months crossed with crosses: placebo fenproporx more dizepam, amfepramona to fenpropore, fenproporex to mazindol and diazepam fenproporex more to D-norpseudoephedrine; to evaluate the safety and efficacy of sequential treatment, in which 120 patients (30 per arm) were included. Results. The results indicate that all combinations significantly decrease the weight (in kilograms absolute and percentage), BMI, fat (kilograms and percentage), waist circumference; and biochemical parameters; however, combination (in sequence) of fenproporex to mazindol was the most effective reduction, although all combinations showed both efficacy and safety in drug treatment as part of integrated management (diet and exercise) of obesity. Conclusion. This study helps support the sequential therapeutic strategy for antiobesity long-term treatment (14 months).

REFERENCES

1. Encuesta Nacional de Salud y Nutrición (ENSANUT), 2012.

2. Enzi G, Baritussio A, Marchiori E, Crepaldi G. Short-term and long-term clinical evaluation of a non-amphetamineic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976; 4: 305.

3. Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Universal Clin Cornerstone 2009; 9(4): 55-68; discussion 69-71.

4. Bray GA. Drug treatment of the overweight patient. Sibutramine, a serotonin-norepinephrine re-uptake inhibitor, facilitated the maintenance of a 10 kg weight loss at 2 years. Gastroenterology 2007; 132: 2239-52.

5. Makoundoua V, Patakya Z, Bobbioni-Harscha E, Gachoudb JP, Habichta F, Golaya A. Multi-factorial approach associated with a new ‘on/off’ Orlistat®. Use in a weight loss maintenance programme: 4 years follow-up. Obesity Facts 2011; 4: 191-6.

6. Torgerson J, Boldrin M, Hauptman J, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (Xendos) study. Diabetes Care 2004; 27(1): 155-61.

7. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; (3).

8. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obeses women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obesity Research 2000; 8(6): 431-7.

9. Ara, Blake, Gray, Hernández, Crowther. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review. Health Technology Assessment 2012; 16: 5.

10. Hendricks E, Rothman R, Greenway F. How physician obesity specialists use drugs to treat obesity. Obesity 2009; 17: 1730-5.

11. Morín Z, Ponce L, Lonngi VS, Alcaraz O, Lonngi VG. Eficacia y seguridad de dos formulaciones de fenproporex de liberaRev Hosp Jua Mex 2014; 81(2): 77-85 Rodríguez-Choreño JD y cols. Anorexigénicos catecolaminérgicos en liberación lenta. 85 ción lenta como tratamiento de obesidad. Revista Mexicana de Cardiología 2005; 16(4): 146-54.

12. Morín ZR, Lonngi G, Alcaraz OR, Rosas HD. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses. Medicina Interna de México 2001, 17(6).

13. Bray G, Greenway F. Current and potential drugs for treatment of obesity. Endocrine Reviews 1999; 20(6): 805-75.

14. Cheung M. Drug treatment for obesity in the post-sibutramine era. Drug Saf 2011; 34(8): 641-50.

15. Cercato C, Roizenblatt VA, Leanca CC, Segal A, Mancini M, Halpern A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes (Lond) 2009; 33: 857-65.

16. De Laet D, Schauer D. Obesity in adults. Clinical Evidence 2011; 03: 604.

17. Adan A, Vanderschuren L, La Fleur S. Anti-obesity drugs and neural circuits of feeding. Trends in Pharmacological Sciences 2008; 29: 4.

18. Billes S, Cowley M. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese. Neuropsychopharmacology 2007; 32: 822-83.

19. Billes S, Cowley M. Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 2008; 33: 1287-97.

20. Kang YM, Ouyang W, Chen JY, Qiao JT, Dafny N. Norepinephrine modulates single hypothalamic arcuate neurons via alpha(1) and beta adrenergic receptors. Brain Res 2000; 869 (1-2): 146-57.

21. Sweeney KF. The anorectic Action of Mazindol. Ir J Med Sc 1978; 147(Supl. 1): 66-70.